
Please try another search
Alfasigma, one of the largest Italian pharma companies, has entered into an agreement to acquire Intercept Pharmaceuticals (NASDAQ:ICPT) for $19 per share in cash.
This move is expected to substantially expand Alfasigma's gastrointestinal and hepatology portfolio, as well as its presence in the U.S. pharmaceutical market, the company said.
“Today’s proposed acquisition is aligned with our strategy to build presence in the U.S. market, with a focus in our core gastroenterological area while adding another important asset to our innovation pipeline. This acquisition will contribute to the ambitious growth strategy designed for our company,” Mr. Stefano Golinelli, Chairman of Alfasigma Board, said.
The purchase price of $19 per share represents an 82% premium over Intercept's closing stock price on September 25, 2023.
Jerry Durso, president and chief executive officer of Intercept said that the deal “recognizes the value of our portfolio, R&D and commercial capabilities and our talented people across the organization.”
The transaction is set to be completed by the end of 2023.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.